Quanterix
Billerica
About Quanterix
Quanterix Corporation is developing a novel platform for single-molecule analysis that will bring an unprecedented level of sensitivity, precision, and assay robustness to clinical diagnostics, drug development, and life science research. Their unique approach permits rapid quantification and analysis of individual proteins and small molecules within complex biological samples, enabling us to address a variety of unmet medical needs. The company’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix’s technology is designed to enable much earlier disease detection, better prognosis, and precise treatment methods to improve the quality of life and longevity of the population for generations to come.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Total funding: $533.3M
- Funding stage: IPO
- Last round: Grant (Mar 2022)
- Ticker: nasdaq:QTRX
- Website: quanterix.com
- Phone: 617-301-9400
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Life Science, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/quanterix-44847 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.